unknown
Stage
1
Investors
About
XWPharma is a Wuhan-based biopharmaceutical company focused on discovery and development of CNS therapeutics for neurological and psychiatric disorders. Its lead program, XW10508, is a Phase 2 oral NMDA antagonist being developed for treatment-resistant depression.
Explore XWPharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.